We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.4B
1-Year Est. Return 163.13%
This Fund
S&P 500
This Quarter Est. Return
+26.01%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$5.4B
AUM Growth
+$351M
Cap. Flow
+$35.9M
Cap. Flow %
0.67%
Top 10 Hldgs %
42.1%
Holding
152
New
38
Increased
33
Reduced
27
Closed
23

Top Buys

Rank Stock Value
1
UNH icon
UnitedHealth
UNH
+$59.7M
2
ODTX
Odyssey Therapeutics
ODTX
+$52.6M
3
ARQT icon
Arcutis Biotherapeutics
ARQT
+$47.6M
4
COGT icon
Cogent Biosciences
COGT
+$47.6M
5
HUM icon
Humana
HUM
+$46.7M

Top Sells

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$54.7M
2
DHR icon
Danaher
DHR
+$50.4M
3
ELVN icon
Enliven Therapeutics
ELVN
+$50.2M
4
BSX icon
Boston Scientific
BSX
+$48.8M
5
IRON icon
Disc Medicine
IRON
+$48.8M

Sector Composition

Rank Sector Weight
1 Healthcare 97.03%
2 Miscellaneous 2.97%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
COGT icon
26
Cogent Biosciences
COGT
$6.02B
$65.1M 1.21%
1,681,300
+1,359,200
+422% +$47.6M
BSX icon
27
Boston Scientific
BSX
$67.9B
$63.3M 1.17%
1,483,200
-898,900
-38% -$48.8M
ISRG icon
28
Intuitive Surgical
ISRG
$132B
$62.8M 1.16%
157,900
-50,800
-24% -$22.2M
MLYS icon
29
Mineralys Therapeutics
MLYS
$2.26B
$56.9M 1.06%
2,110,300
+57,400
+3% +$1.57M
ODTX
30
Odyssey Therapeutics
ODTX
$1.17B
$56.2M 1.04%
+3,001,198
New +$52.6M
XENE icon
31
Xenon Pharmaceuticals
XENE
$5.81B
$53.9M 1%
892,471
-167,500
-16% -$9.3M
ARQT icon
32
Arcutis Biotherapeutics
ARQT
$2.99B
$53.5M 0.99%
+2,042,000
New +$47.6M
BMY icon
33
Bristol-Myers Squibb
BMY
$136B
$53.3M 0.99%
925,000
– –
QTTB icon
34
Q32 Bio
QTTB
$447M
$52.6M 0.97%
4,127,987
+1,875,000
+83% +$15.7M
SYK icon
35
Stryker
SYK
$127B
$50.1M 0.93%
159,100
-23,400
-13% -$7.37M
CAI
36
Caris Life Sciences
CAI
$7.24B
$50M 0.93%
2,806,811
– –
XBI icon
37
PUT
State Street SPDR S&P Biotech ETF
XBI
$11.3B
$47.5M 0.88%
+300,000
New +$40.6M
TMO icon
38
Thermo Fisher Scientific
TMO
$230B
$45.5M 0.84%
90,700
+44,200
+95% +$21.2M
PVLA
39
Palvella Therapeutics
PVLA
$2.16B
$44.7M 0.83%
292,360
+157,760
+117% +$19.1M
ELV icon
40
Elevance Health
ELV
$85.5B
$44.4M 0.82%
114,700
– –
STTK icon
41
Shattuck Labs
STTK
$707M
$43.8M 0.81%
6,306,127
– –
UPB
42
Upstream Bio Inc
UPB
$366M
$39.4M 0.73%
5,693,589
– –
CRNX icon
43
Crinetics Pharmaceuticals
CRNX
$9B
$37.4M 0.69%
999,000
– –
RYTM icon
44
Rhythm Pharmaceuticals
RYTM
$7.38B
$35.9M 0.66%
322,900
+8,800
+3% +$796K
SNDX icon
45
Syndax Pharmaceuticals
SNDX
$1.74B
$33.7M 0.62%
1,542,000
+579,700
+60% +$12.1M
FBRX icon
46
Forte Biosciences
FBRX
$33.5M 0.62%
1,577,705
+380,750
+32% +$9.03M
CMPX icon
47
Compass Therapeutics
CMPX
$432M
$33.3M 0.62%
15,219,994
– –
NKTR icon
48
Nektar Therapeutics
NKTR
$2.48B
$32.5M 0.6%
465,346
+190,346
+69% +$13.9M
KRYS icon
49
Krystal Biotech
KRYS
$10.4B
$30.9M 0.57%
83,200
+14,100
+20% +$4.21M
AXSM icon
50
Axsome Therapeutics
AXSM
$10.4B
$28.8M 0.53%
117,578
-96,343
-45% -$20.9M
1
2
3 4 5

Similar funds

MYIA
Mount Yale Investment Advisors Denver, Colorado $5.4B AUM 28.46% 1-Year Est. Return
SCM
Shelton Capital Management Denver, Colorado $5.39B AUM 56.42% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
SNT
SIG North Trading Bala Cynwyd, Pennsylvania $5.42B AUM 31.03% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
RC
Resolution Capital Sydney, NSW, Australia $5.44B AUM 27.71% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return

OrbiMed's Q2 2026 Portfolio in Review

As of Q2 2026, OrbiMed held 152 positions worth $5.4B, up 7% from $5.05B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

OrbiMed's Q2 2026 filing shows 38 new, 33 increased, 27 reduced and 23 closed positions. Its largest new stake was UnitedHealth: 161,100 shares worth $67M. The largest sale was Pfizer, an estimated $54.7M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 90% a quarter earlier, followed by Miscellaneous.

  • OrbiMed's largest Q2 2026 buy was UnitedHealth: 161,100 shares worth $67M.
  • OrbiMed added most to Cogent Biosciences in Q2 2026, an estimated $47.6M increase.
  • OrbiMed's biggest Q2 2026 reduction was Enliven Therapeutics, cutting an estimated $50.2M.
  • OrbiMed fully exited Pfizer in Q2 2026, selling an estimated $54.7M.
  • OrbiMed's ten largest holdings make up 42% of its $5.4B portfolio in Q2 2026.
  • OrbiMed opened 38 new positions and closed 23 in Q2 2026.
  • OrbiMed's portfolio value rose 7% quarter-over-quarter to $5.4B.

Based on OrbiMed's 13F filing for Q2 2026, filed 14 Aug 2026.